التفاصيل البيبلوغرافية
| العنوان: |
Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study |
| المؤلفون: |
Brandon T. McDaniel, Victor Cornet, Jeanne Carroll, Lambros Chrones, Joseph Chudzik, Jeanette Cochran, Shion Guha, Debra F. Lawrence, Maggie McCue, Sara Sarkey, Betty Lorenz, Jay Fawver |
| المصدر: |
BMC Psychiatry, Vol 23, Iss 1, Pp 1-14 (2023) |
| بيانات النشر: |
BMC, 2023. |
| سنة النشر: |
2023 |
| المجموعة: |
LCC:Psychiatry |
| مصطلحات موضوعية: |
Depression severity, Major depressive disorder, Patient-reported outcome measures, Real-world clinical practice setting, Vortioxetine, Comorbid psychiatric diagnoses, Psychiatry, RC435-571 |
| الوصف: |
Abstract Background This study included evaluation of the effectiveness of vortioxetine, a treatment for adults with major depressive disorder (MDD), using patient-reported outcome measures (PROMs) in a real-world setting. Methods This retrospective chart review analyzed the care experiences of adult patients with a diagnosis of MDD from Parkview Physicians Group – Mind-Body Medicine, Midwestern United States. Patients with a prescription for vortioxetine, an initial baseline visit, and ≥ 2 follow-up visits within 16 weeks from September 2014 to December 2018 were included. The primary outcome measure was effectiveness of vortioxetine on depression severity as assessed by change in Patient Health Questionnaire-9 (PHQ-9) scores ~ 12 weeks after initiation of vortioxetine. Secondary outcomes included changes in depression-related symptoms (i.e., sexual dysfunction, sleep disturbance, cognitive function, work/social function), clinical characteristics, response, remission, and medication persistence. Clinical narrative notes were also analyzed to examine sleep disturbance, sexual dysfunction, appetite, absenteeism, and presenteeism. All outcomes were examined at index (start of vortioxetine) and at ~ 12 weeks, and mean differences were analyzed using pairwise t tests. Results A total of 1242 patients with MDD met inclusion criteria, and 63.9% of these patients had ≥ 3 psychiatric diagnoses and 65.9% were taking ≥ 3 medications. PHQ-9 mean scores decreased significantly from baseline to week 12 (14.15 ± 5.8 to 9.62 ± 6.03, respectively; p |
| نوع الوثيقة: |
article |
| وصف الملف: |
electronic resource |
| اللغة: |
English |
| تدمد: |
1471-244X |
| Relation: |
https://doaj.org/toc/1471-244X |
| DOI: |
10.1186/s12888-023-05439-8 |
| URL الوصول: |
https://doaj.org/article/461fc965bd8d48ea88008ac5ac8f8858 |
| رقم الانضمام: |
edsdoj.461fc965bd8d48ea88008ac5ac8f8858 |
| قاعدة البيانات: |
Directory of Open Access Journals |
Full Text Finder